Proliferative T cell responses to four human cytomegalovirus-specific proteins in healthy subjects and solid organ transplant recipients.

It is still poorly understood which of the cytomegalovirus (CMV)-induced proteins are important for the host's cellular immunity during active infection and for establishing latency. To answer this question, in vitro proliferative T cell responses to four recombinant CMV proteins were compared and compared with responses to CMV-infected fibroblasts in immunocompetent healthy CMV-seropositive subjects and immunocompromised organ transplant recipients. The proteins studied were the lower matrix protein pp65 (ppUL83), the DNA-binding protein p52 (ppUL44), and the two immediate-early proteins IE1 (UL123) and IE2 (UL122). In healthy persons, pp65 was the most important protein with respect to its ability to induce a proliferative T cell response. In transplant recipients, severe suppression of the responses to these CMV proteins was found. This finding may be clinically relevant in view of the occurrence and course of CMV infection in these patients.

Humoral immune response against human cytomegalovirus (HCMV)-specific proteins after HCMV infection in lung transplantation as detected with recombinant and naturally occurring proteins.

The humoral immune response to four intracellularly located cytomegalovirus (CMV) proteins was studied in 15 lung transplant recipients experiencing active CMV infections. Five patients had primary infections, and 10 had secondary infections. Antibodies of the immunoglobulin M (IgM) and IgG classes were measured in an enzyme-linked immunosorbent assay (ELISA) system in which procaryotically expressed recombinant proteins were used as a substrate and also in a monoclonal antibody-based capture ELISA which uses naturally occurring proteins as a substrate. The proteins investigated were the lower matrix protein pp65 (ppUL83), the major DNA-binding protein p52 (ppUL44), and the two immediate early proteins IE1 and IE2 (different splicing products of UL123). Higher levels of antibodies were found to pp65 and especially to p52 than to the immediate early antigens. Antibody levels detected in the recombinant protein-based ELISAs were generally lower than antibody responses detected with the matching antigen capture ELISA. Moreover, some patients appeared to have antibodies mainly to epitopes present on naturally occurring proteins. The antibody responses detected in both assays were related to the viral load during infection as assessed by the CMV antigenemia test, which is a quantitative marker for CMV load. It was found that although epitopes on naturally occurring proteins induce higher antibody responses and responses in more patients, antibodies directed to epitopes present on the recombinant proteins were inversely related to the viral load during a CMV infection. Therefore, antibodies to epitopes on the recombinant proteins might be more clinically relevant in this group of lung transplant recipients.

Presence of human cytomegalovirus (HCMV) immediate early mRNA but not ppUL83 (lower matrix protein pp65) mRNA in polymorphonuclear and mononuclear leukocytes during active HCMV infection.

During an active human cytomegalovirus (HCMV) infection, leukocytes, harbouring the HCMV lower matrix protein pp65 (ppUL83) are present in the peripheral blood and can be detected with the HCMV antigenaemia assay. In the present study, it was investigated whether the presence of pp65 in these cells was due to transcription of the virus genome or might be the result of uptake of this viral protein. Peripheral blood leukocytes of transplant recipients and AIDS patients with an active HCMV infection were investigated for the presence of HCMV immediate early (IE) antigen and pp65 using well characterized monoclonal antibodies, and for the presence of the corresponding mRNAs using non-radioactive in situ hybridization. Both mononuclear and polymorphonuclear cells were found to contain IE antigen and pp65. However, only mRNAs encoding IE antigen were found in these cells, whereas mRNAs encoding pp65 were not detected. In contrast, both IE antigen and pp65, as well as their corresponding mRNAs, were detected in the circulating late-stage HCMV-infected endothelial cells that were also present in the leukocyte fractions. These findings demonstrate that a restricted viral gene expression (transcription of IE genes) does occur in mononuclear and polymorphonuclear leukocytes. However, the abundant presence of the early antigen pp65 without detectable presence of the corresponding mRNA in these cells strongly indicates uptake of this protein by the phagocytic leukocytes, rather than de novo synthesis.

Natural killer cell responses in renal transplant patients with cytomegalovirus infection.

Natural killer (NK) cell function in relation to immunophenotypical signs of NK activation was studied prospectively in 15 renal transplant patients with cytomegalovirus (CMV) infection. NK activity (expressed as the percentage of K562 lysis) before onset of CMV infection reached a median of 6% (range 2-18%), comparable to values observed in noninfected controls [7% (range 7-21%), P < .1]. During CMV infection, NK activity rose to a maximum of 25% (6-60%) (P < .001 vs. controls). Maximal values exceeded the upper level of controls in nine of 15 patients. NK activity was correlated to the number of CD56+HLADR+ cells in the peripheral blood (r = .57, P < .001). These data suggest that NK cells play a role in the recovery from CMV infection in a substantial number of patients and that immunophenotypical analysis of NK activation provides a surrogate marker of NK cell function.

Ultrastructural analysis of circulating cytomegalic cells in patients with active cytomegalovirus infection: evidence for virus production and endothelial origin.

The presence of cytomegalic inclusion cells in the peripheral blood of patients with an active cytomegalovirus infection has recently been demonstrated. Immunologic staining showed that these cells were of endothelial origin. Study of circulating cytomegalic cells by transmission electron microscopy showed the cells to be productively infected with cytomegalovirus. Viral capsids were present in the nucleus and virus particles and dense bodies were found in the cytoplasm. The results indicate that these circulating cytomegalic cells could disseminate cytomegalovirus throughout the body. In addition, the finding of a cluster of cytomegalic cells in the peripheral blood linked together by zonula adherens type cell junctions is further evidence that these cells are of endothelial origin and suggests that the endothelial damage may be extensive.

Prediction of recurrent cytomegalovirus disease after treatment with ganciclovir in solid-organ transplant recipients.

CMV disease often recurs after initially successful antiviral therapy. We retrospectively determined in a group of 36 organ transplant patients whether clinical, virological, or immunological parameters during or shortly after cessation of antiviral therapy can identify those at high risk of relapse. Eleven of 36 patients had recurrent CMV disease after ganciclovir therapy. Neither donor or recipient CMV serostatus, type of baseline immunosuppression, antirejection treatment, indication for antiviral treatment, nor presence of CMV in the blood during or after therapy (as detected by antigenemia, viremia, or a positive polymerase-chain-reaction signal) were helpful in identification of patients with subsequent relapse. However, quantitative monitoring of antigenemia fascilitated early diagnosis of relapse since 10 of 11 patients with > or = 10 antigen-positive cells per 50,000 PMNs relapsed (99.1%, 95% CI 58.7-99.8). IgM and IgG responses against CMV during primary infection were comparable in relapsing and nonrelapsing patients. During secondary infection relapse occurred only in the 4 patients with the lowest IgG responses. The number of activated CD8bright lymphocytes in the peripheral blood as determined by flow cytometry at the end of antiviral therapy was a strong risk factor for the subsequent clinical course: 6 of 7 patients (85.7%, 95% CI 42.1-99.6%) with < 100 x 10(3) HLADR+CD8bright cells/ml blood relapsed, while 8 of 8 (100%, 95% CI 63-100) with activated CD8bright cells above that level remained asymptomatic (P < .025). These data show that patients with a high risk of relapse of CMV disease can be identified at the end of antiviral therapy.

Circulating cytomegalovirus (CMV)-infected endothelial cells in patients with an active CMV infection.

In 10 of 14 patients with an active cytomegalovirus (CMV) infection, distinctive large cells (35-45 microns in diameter) were present in the peripheral blood. Morphologically these cells closely resembled the classic cytomegalic inclusion cells, generally regarded as a diagnostic hallmark of CMV infection. Moreover, these cells were shown to express CMV antigens belonging to all three stages of the viral replication cycle, indicating a productive CMV infection. In addition, immunologic staining with monoclonal antibodies directed against cell differentiation and marker proteins showed that these circulating cytomegalic cells were of endothelial origin. The presence of CMV-infected endothelial cells in the peripheral blood of patients with an active CMV infection indicates that such an infection might be accompanied by widespread occult vascular damage.

Antibody responses to human cytomegalovirus-specific polypeptides studied by immunoblotting in relation to viral load during cytomegalovirus infection.

The humoral immune response to individual proteins of human cytomegalovirus (CMV) was studied by immunoblotting. CMV polypeptides present in an extract of CMV-infected fibroblasts in a late stage of infection were recognized by sera of healthy seropositive individuals and transplant recipients who suffered from a primary or secondary CMV infection. The results showed that the sera reacted with a maximum number of 18 polypeptides ranging in molecular weight from 28-235 kDa. In 60% or more of the healthy seropositives, polypeptides were recognized with an apparent molecular weight of 150, 98, 94, 58, 50, 44, 38, and 32 kDa. In the patient group, the most immunogenic polypeptides were those with an apparent molecular weight of 150, 104, 94, 66, 50, 38, and 32 kDa. A correlation was found between the antibody levels in sera from the healthy seropositives and the number of recognized polypeptides but no such relationship was seen in the transplant recipients. However, sera of patients with a high virus load during their secondary CMV infection, as detected by the CMV-antigenemia test, appeared to react less frequently and less intensely with the polypeptides than those with low viremia. A high number of antigen-positive leukocytes in the CMV-antigenemia test was related to a low frequency of polypeptides with molecular weights of 85, 76, 66, 44, 38, and 32 kDa recognized before transplantation.

Recovery from cytomegalovirus infection is associated with activation of peripheral blood lymphocytes.

The number of CD8bright and CD56+ lymphocytes in the peripheral blood and their activation status were monitored by flow cytometry in 23 renal transplant recipients with cytomegalovirus (CMV) infection and were correlated with the virus load (as determined by CMV antigenemia) and clinical symptoms. Recovery from CMV infection coincided with expansion of the CD8bright and CD56+ subsets and with increased expression of the activation marker HLA-DR. Primary infection was associated with activation of both subsets, whereas during secondary infection, mainly CD8bright cells responded. Progressive CMV disease (requiring antiviral treatment) and relapse occurred in association with low numbers of activated CD8bright and CD56+ cells. Lymphocyte activation and antibody responses against CMV often occurred simultaneously, but different kinetics of these responses in some patients indicated that cellular responses are necessary to control viral replication, whereas humoral responses alone may be insufficient. Monitoring of lymphocyte activation may provide clinically useful information during CMV infection.

The lower matrix protein pp65 is the principal viral antigen present in peripheral blood leukocytes during an active cytomegalovirus infection.

During an active infection with human cytomegalovirus (HCMV), viral antigen is consistently present in peripheral blood leukocytes. Two monoclonal antibodies (MAbs), CMV-C10 and CMV-C11, are commonly used in the HCMV antigenaemia assay to detect these cells in the peripheral blood of patients suspected of having an active HCMV infection. We demonstrate that the viral antigen detected by these MAbs is the viral structural protein pp65 and not an immediate early antigen as previously reported. Furthermore, significantly fewer leukocytes were found to be positive with MAbs specific for immediate early antigens.

Monitoring antigenemia is useful in guiding treatment of severe cytomegalovirus disease after organ transplantation.

We investigated the value of monitoring CMV antigenemia during and after antiviral therapy for CMV disease. During the study period, 10 out of 214 renal transplant recipients were treated for CMV disease, receiving a total of 14 courses of treatment. Antigenemia decreased within 7 days after onset of treatment in eight of nine courses associated with a rapid clinical recovery. In three courses with a slow or absent response, antigenemia levels initially increased. Monitoring antigenemia was helpful in differentiating persisting CMV disease from other opportunistic infections and rejection. Relapses of CMV disease were preceded by rises in antigenemia. Viral isolation became negative within 3 days after initiation of ganciclovir, irrespective of the clinical response. Antigenemia is a marker of the effect of ganciclovir on CMV replication in vivo, and its monitoring may be valuable in the management of patients with severe CMV disease.

Antigenemia in the diagnosis and monitoring of active cytomegalovirus infection after liver transplantation.

In 45 liver transplant recipients, the value of weekly monitoring of cytomegalovirus (CMV) antigenemia for early diagnosis of active CMV infection was compared with serology and rapid viral isolation. Active CMV infection occurred in 23 patients. The sensitivities of the antigenemia assay and serology (of blood) and rapid viral isolation (from blood or urine) were 96%, 96%, 57%, and 70%, respectively. First diagnostic results of these methods were obtained a median of 25, 36, 31, and 49 days, respectively, after transplant. CMV infection was symptomatic in 20 patients; antigenemia was present at the onset of disease in 13 of these. Maximum CMV antigenemia levels were higher in patients with severe disease than in those with mild or asymptomatic infection. CMV antigenemia is a sensitive, early, quantitative marker of active CMV infection after liver transplantation.

Predominance of IgG1 and IgG4 subclasses of anti-neutrophil cytoplasmic autoantibodies (ANCA) in patients with Wegener's granulomatosis and clinically related disorders.

In view of the supposed hypersensitivity, the elevated levels of IgE, and the occurrence of eosinophilia reported in Wegener's granulomatosis and related conditions, we studied the IgG subclass distribution of ANCA directed against a 29-kD serine protease and myeloperoxidase (MPO) in 41 untreated ANCA-positive patients with several forms of active vasculitis and/or glomerulonephritis. We found that both 29-kD ANCA and MPO ANCA were predominantly of the IgG1 and IgG4 subclass in all groups of patients. The additional presence of IgG3 subclass was associated with renal involvement. We compared the subclass distribution of ANCA with that of total IgG subclass levels, and with the IgG subclass distribution of antibodies to cytomegalovirus (CMV) as a persistent endogenous antigen and antibodies to tetanus toxoid (TT) as an exogenous recall antigen. Total levels of IgG4 were elevated in the majority of the patients together with elevated IgG1 levels. Antibodies to CMV and TT, however, had the same subclass distribution as found in normals and did not show enhanced IgG4 expression. ANCA belong predominantly to the IgG1 and IgG4 subclass, which may suggest that the production of ANCA is related to recurrent exposition to the antigen(s) involved, possibly as part of a hypersensitivity reaction.

Cytomegalovirus-specific antibodies to an immediate early antigen and a late membrane antigen and their possible role in controlling secondary cytomegalovirus infection.

In 24 renal transplant recipients who had a secondary cytomegalovirus (CMV) infection, the magnitude and development of CMV-specific antibodies directed against two different antigens were studied in relation to the presence of CMV-immediate early antigen-positive peripheral blood leucocytes (CMV antigenaemia). These antibodies were measured in an antigen-capture ELISA using two monoclonal antibodies: one directed against the major immediate early antigen (IEA) and a second one directed against the CMV-encoded glycoprotein B (gB). A statistically significant inverse relationship between the level of anti-IEA antibodies present at the time of transplantation as well as the magnitude of the increase of these antibodies during CMV infection and the maximum number of IEA-positive cells during infection was shown. In contrast, both anti-gB and anti-total CMV antibodies did not give any correlation with the CMV antigenaemia. This may indicate that the anti-IEA immune response plays a role in defence mechanisms against a CMV infection.